Agreed....
P value low
n very low (15 !!)
means drug effect size is up...
Wait till our P3 comes in when n is greater than 15 !?! What is that going to do to P on the assumption that drug effect size stays constant? (As it has done in all the other clinical trials and studies).
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-6
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $85.7M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 24.5¢ | 24.5¢ | $31.10K | 126.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 146333 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 50464 | 4 |
View Market Depth
| Last trade - 16.10pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
25.0¢ |
Change
0.000 ( 2.04 %) |
||||
| Open | High | Low | Volume | ||
| 24.5¢ | 25.0¢ | 24.5¢ | 58268 | ||
| Last updated 15.27pm 07/06/2024 ? | |||||
| PAR (ASX) Chart |